Physician profile
Daniel Sellers
NPI 1841693819
$119,983.41
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $71K · 2022: $49K.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $62,572.97 | 2021-2022 | |
| Biogen, INC. | $31,174.45 | 2021-2022 | |
| Genzyme Corporation | $15,125.55 | 2021-2022 | |
| Celgene Corporation | $4,073.55 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $3,243.01 | 2022 | |
| Banner Life Sciences, LLC | $812.98 | 2021-2022 | |
| Tg Therapeutics, INC. | $765.00 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $524.22 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $295.86 | 2022 | |
| Novartis Pharmaceuticals Corporation | $239.21 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $216.65 | 2022 | |
| Abbvie INC. | $208.23 | 2021-2022 | |
| Centinel Spine, LLC | $154.71 | 2022 | |
| Sk Life Science, INC. | $140.83 | 2022 | |
| Harmony Biosciences LLC | $73.08 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $68.17 | 2021 | |
| Genentech USA, INC. | $48.73 | 2022 | |
| Janssen Pharmaceuticals, INC | $44.08 | 2022 | |
| Sunovion Pharmaceuticals INC. | $32.31 | 2021 | |
| Mallinckrodt Hospital Products INC. | $30.83 | 2022 | |
| Djo, LLC | $27.26 | 2022 | |
| Nevro Corp. | $26.34 | 2022 | |
| Horizon Therapeutics Plc | $22.24 | 2021 | |
| Ucb, INC. | $20.78 | 2022 | |
| Xeris Pharmaceuticals, INC. | $15.93 | 2022 | |
| Supernus Pharmaceuticals, INC. | $14.60 | 2021 | |
| Amgen INC. | $11.84 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Sellers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.